Achieving Sustainable Development Goal targets for 2030 will require persistent investment and creativity in improving access to quality health services, including skilled attendance at birth and access to emergency obstetric care. Community-based misoprostol has been extensively studied and recently endorsed by the WHO for the prevention of postpartum haemorrhage. There remains little consolidated information about experience with implementation and scale-up to date. This narrative review of the literature aimed to identify the political processes leading to WHO endorsement of misoprostol for the prevention of postpartum haemorrhage, and describe ongoing challenges to the uptake and scale-up at both policy and community levels. We review the peer-reviewed and grey literature on expansion and scale-up and present the issues central to moving forward.
Uterotonics are arguably the most essential component of AMTSL (Gülmezoglu et al., 2012) . Oxytocin remains the gold standard uterotonic of choice (World Health Organization, 2012a) . Every major international oversight body recommends intravenous or intramuscular oxytocin for the prevention of PPH, and a tablet-form uterotonic, misoprostol (600 mcg oral), if and when oxytocin is not available (World Health Organization, 2012a) .
Oxytocin is heat labile and administered via injection, and thus often inaccessible to women giving birth outside health facilities (Raghavan, Abbas, & Winikoff, 2012; World Health Organization, 2012a) . In practice, even when SBAs are equipped with oxytocin for home and facility births, it is often stored incorrectly and thus less efficacious (Torloni, Freitas, Kartoglu, Gulmezoglu, & Widmerc, 2016; Wilson et al., 2012) .
Recent efforts have focused on the use of misoprostol to reach women who deliver at home without a SBA.
Misoprostol is a synthetic prostaglandin E1 originally developed for the prevention and treatment of gastric ulcers in 1985 (Garris & Kirkwood, 1989) . Compared to oxytocin, misoprostol does not require refrigeration, and can be administered orally, sublingually, rectally and vaginally (Wise & Clark, 2008) . Giving birth with an SBA is still recommended as the most essential step to decrease maternal mortality, and full coverage of facility births remains the ultimate goal (Murthy & Smith, 2009) . Until every woman has access to an SBA, however, experts argue that the community distribution of misoprostol is a scalable and relatively safe intervention to reduce PPH (Oladapo, 2012; Prata, N. et al., 2011b; Smith, J. M., Gubin, Holston, Fullerton, & Prata, 2013) . The WHO includes misoprostol for the prevention of PPH on the Essential Medicine List and community-based distribution (CBD), but has yet to recommend the advance distribution of misoprostol for self-administration (ADMSA) (World Health Organization, 2012a ).
This narrative review aims to explore the context for on-going tensions between policy and practice surrounding the community-based distribution of misoprostol for PPH in low-income settings. advance We present a broad literature review and update the existing pilot studies on community-based distribution of misoprostol. We then outline the existing literature on expansion and scale-up to help understand why efforts to increase the availability of misoprostol in community settings countries have been protracted.
Methodology

Review methodology
A narrative review of both the qualitative and quantitative data was chosen over a systematic review to include both experimental and non-experimental descriptive studies (Whittemore & Knafl, 2005) as well as grey literature with narrative descriptions of programme challenges (Slavin, 1995) . An initial set of papers were identified using the literature review strategy below, including "scale" and "scale-up" to broaden the scope of previous reviews. We conducted forward snowballing from the references of papers that met inclusion criteria. Grey literature searches from UN agencies, governmental and non-government organisations websites and reports were included. Ethical clearance was obtained from the Human Research Ethics Committee at Charles Darwin University, Australia (HREC 2015 (HREC -2445 .
Literature review strategy
This review was conducted using four databases: Medline, Cochrane Review Library, CINAHL and ProQuest Dissertation & Theses Database. The search strategy included a combination of terms, including 'misoprostol'; 'postpartum haemorrhage' (and variations i.e. 'postpartum haemorrhage', 'post-partum hemorrhage') 'community-based maternal'; 'maternal'; 'maternal health interventions'; 'maternal mortality'; 'low-income setting'; 'developing country'; 'resource-poor setting'; 'traditional birth attendant'; 'scale' and 'scale-up'.
Inclusion and exclusion criteria
Dates were not restricted up until March 1 st , 2016. Only English articles or those with an English translation were included. KH screened the literature for relevance to programmes using all modes of administration and doses of misoprostol for the prevention of PPH. Articles were excluded if the research took place in high-income countries, defined by a GNI per capita higher than 12 476 USD (World Bank, 2016) . Articles were also excluded if conducted exclusively in clinical settings without a community component and if not specific to misoprostol; for example, TBA programmes that did not use misoprostol, or misoprostol for an indication other than the prevention of PPH, including abortion or induction of labour.
Results
A total of 249 articles were retrieved and screened from our search strategy. Of these, 135 full text articles were assessed for eligibility. See Figure 1 . In total, 84 articles were eligible. Findings were organized into four major categories: evidence for the use of misoprostol in community settings; political momentum for the CBD of misoprostol, challenges to uptake in community settings; and the expansion and scale-up of CBD misoprostol. .
A total of 24 articles were included in the synthesis of CBD pilot studies. Many of these trials published before 2013 were detailed in the Smith et al. (2013) review of global implementation of misoprostol. The seven studies published after the 2013 review are outlined in Table 1 .We identified nine studies of "scale", defined for the purposes of this review as deliberate post-pilot efforts to expand CBD programs or include CBD of misoprostol in a national policy or operational plan. These are outlined in Table 2 .
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Evidence for Community-based Distribution of Misoprostol for the prevention of PPH
As early as 2002, a number of countries introduced pilot studies to assess the feasibility of distribution of misoprostol through CHWs or antenatal care (ANC) visits, with promising results (Derman et al., 2006; Mobeen et al., 2011; Prata, N, Mbaruku, Campbell, Potts, & Vahidnia, 2005; Rajbhandari et al., 2010; Sanghvi et al., 2010; Sanghvi, Wiknjosastro, Chanpong, Fishel, & Ahmed, 2004) . Findings from the seven pilot studies published after the Smith et al. review (2013) , outlined in Table 1 , drew similar conclusions to previous studies. Most trials concluded that women who used misoprostol self-reported significantly less heavy bleeding than those who did not receive uterotonics; where bleeding was objectively measured, the rate of PPH was significantly lower compared to placebo or no uterotonic.
Most studies also measured significantly fewer bleeding-related referrals. The vast majority of women enrolled were able to correctly administer the medicine themselves or with the assistance of a community-based worker. Studies were often hosted in areas with very poor access to assisted deliveries, and misoprostol invariably increased uterotonic coverage -from 11.6% to 74.2% in 1 district of Nepal, for example (Rajbhandari et al., 2010) . Community-based distribution of misoprostol nearly doubled the coverage rate versus distribution through health workers or ANC visits;
in South Sudan, a 2014 study showed an even more dramatic difference in coverage when the drug is distributed via ANC versus home visits (17.2% versus 82.8%) (Smith, J.M., Baawo, S.D., et al., 2014) . Low coverage achieved in the Liberian study (24% of home births) was attributed to reliance on skilled heath providers to counsel and distribute misoprostol. Several studies also documented that TBA and self-administered misoprostol programmes can work to bolster access to SBAs (Haver, Ansari, Zainullah, Kim, & Tappis, 2016; Prata, N. et al., 2011b) . Acceptability was universally high: 87 -99% of women would recommend misoprostol, and 54.6% -95% were willing to pay. Several reviews have now examined the evidence for CBD of misoprostol for prevention of PPH, with similar conclusions (Flandermeyer, Stanton, & Armbruster, 2010; Smith, H. J. et al., 2015; Smith, J. M. et al., 2013) . Two systematic reviews limited to randomized controlled trials (RCTs) of misoprostol in community settings were inconclusive, and called for large RCTs to confirm the safety and effectiveness of both CBD and ADMSA (Hundley et al., 2013; Oladapo, 2012) .
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Political momentum for the Community-based Distribution of Misoprostol
The grey literature revealed a number of key political events that enabled misoprostol to be used in community settings for PPH. We present a chronological timeline in Figure 2 . In spite of the lack of WHO support and approval, several countries had already taken steps to initiate the use of misoprostol for the prevention of PPH. In January 2006, Nigeria became the first country in the world to register misoprostol for prevention and treatment of PPH (Jadesimi & Okonofua, 2006 ). Ethiopia and Tanzania followed later that year, including misoprostol for PPH prevention on their respective National Essential Medicines List (Campbell & Holden, 2006) .
With growing evidence and advocacy by maternal health experts, misoprostol was added to the WHO's Essential Medicines List in 2011 'for prevention of post-partum hemorrhage where oxytocin is not available or cannot be safely used' (World Health Organization, 2011, p. 29) . In 2012, the WHO formally endorsed the administration of misoprostol for PPH prevention: 'In settings where SBAs are not present and oxytocin is unavailable, the administration of misoprostol (600 µg PO) by community health care workers and lay health workers is recommended for the prevention of PPH' (World Health Organization, 2012a, p. 5). In the same year, the WHO explicitly recognised that CHWs could contribute significantly to reduce PPH through the administration of misoprostol after home births (World Health Organization, 2012b) . This 2012 endorsement is considered a major turning point in garnering international support to use misoprostol for prevention of PPH (Karanja, Muganyizi, Rwamushaija, Hodoglugil, & Holm, 2013) . The WHO upheld the recommendation for use of misoprostol for prevention of PPH in 2015 (World Health Organization, 2015a).
The WHO has yet to recommend the ADMSA. They cite the need for further research on safety, efficacy and coverage (World Health Organization, 2012a). Advance distribution achieves significantly higher uterotonic coverage at birth, and advocates see the lack of WHO endorsement of ADMSA as a major barrier to uptake (Smith, J.M., Baawo, S.D., et al., 2014; Smith, J. M. et al., 2013; Wells, E. et al., 2014) .
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Challenges to implementing misoprostol programmes in community settings
The literature is dotted with potential challenges to using misoprostol as an effective, alternative uterotonic in the absence of oxytocin, despite WHO endorsement (Chu, Brhlikova, & Pollock, 2012; Hundley et al., 2013; Oladapo, 2012; Starrs & Winikoff, 2012) . The reasons for this are multifold: lack of direct evidence for reducing maternal mortality; safety and side effects; fear of misuse; reluctance to invest in CHWs; and detraction from facility-based births. One review specifically examined the barriers to implementation of community-based misoprostol programmes for prevention of PPH, and identified similar results (Smith, H. J. et al., 2015) .
Lack of evidence for impact on maternal mortality
Misoprostol for prevention of PPH lacks direct evidence in reducing maternal deaths (Chu et al., 2012; Hofmeyr, Gulmezoglu, Novikova, & Lawrie, 2013; Hundley et al., 2013) . RCTs comparing misoprostol to placebo in community distributions noted significant reductions in the incidence of PPH (Derman et al., 2006; Mobeen et al., 2011) .
However, some argue this is insufficient evidence for real reductions in maternal mortality (Chu et al., 2012; Oladapo, 2012) .
Direct evidence on maternal mortality reduction is exceedingly difficult to measure given maternal mortality is a relatively rare event (Hofmeyr et al., 2009) . A 2012 Cochrane systematic review assessed the effectiveness and safety of advance misoprostol distribution for PPH prevention and treatment in non-facility births (Oladapo, Fawole, Blum, & Abalos, 2012) . Due to design flaws, no studies met the inclusion criteria. The lack of evidence regarding the direct impact on the reduction of maternal mortality remains a key concern for some policy and health experts.
Safety and side effects
The safety and side effect profile of misoprostol continues to be cited as a concern. Shivering, fever, nausea and diarrhea are commonly reported side effects (Gülmezoglu et al., 2001; Oladapo, 2012) . In several studies, the incidence of side effects has been significantly higher in misoprostol groups (Mobeen et al., 2011; Patted et al., 2009; Weeks et al., 2015) . In a pilot study in Afghanistan, however, reported side effects were lower in the intervention group . Many argue that the side effects are well understood, and can be easily managed (Grossman, Graves, Rwamushaija, & Park, 2010; Oladapo, 2012) .
Uterine rupture is the most serious risk associated with misoprostol if taken before birth, which is true for any uterotonic (Hofmeyr, Say, & Gülmezoglu, 2005) . A Cochrane review found no significant difference in maternal deaths or severe morbidity with misoprostol versus other uterotonics for the prevention or treatment of PPH (Hofmeyr et al., 2013) .
Fear of misuse
Another challenge to wide-scale acceptance of misoprostol for PPH prevention is potential misuse. AHowever, available evidence suggests that both misuse and diversion is uncommon. For example, mistimed administration of misoprostol in CBD programmes were reported as minimal (0.6%) in a global mapping study (Grenier, 2013) . In a Ugandan study of 700 women, only two women had taken either misoprostol or placebo tablets early while the fetus was still in utero (Weeks et al., 2015) . Similarly, in Liberia, only three of 265 women took misoprostol prior to giving birth (Smith, J.M., Baawo, S.D., et al., 2014) . No adverse outcomes were reported in either study. A doctoral thesis on misuse of uterotonics in Southern Nepal found that over 90% of oral uterotonics were administered correctly according to FIGO guidelines (Connor, 2013) .
Concern that misoprostol will be used for elective abortion is an ongoing concern. (Bazzano, Jones, & Ngo, 2014; Coeytaux et al., 2014; . When misoprostol is used alone, it is 85% effective in termination of pregnancy under 12 weeks (International Women's Health Coalition & Gynuity Health
Projects, 2010). Several governments in countries where elective abortion is illegal have restricted access to misoprostol for fear it will be used for termination of pregnancies Kulczycki, 2011; Kumar, 2012) . Another fear is that CHWs will use misoprostol inappropriately to induce labour (Grenier, 2013; Smith, H. J. et al., 2015) . There is, however, no evidence to suggest that misoprostol distributed for the purpose of the prevention of PPH is being diverted for labour induction or pregnancy termination (Grenier, 2013; Starrs & Winikoff, 2012) . The Hundley et al. (2013) systematic review concluded that while most women take the drug at the appropriate time, more research is needed to inform safety protocols and communication strategies.
Reluctance to invest in CHWs
After major investment in TBA training programmes in the 1970s and 80s, a meta-analysis revealed minimal impact on maternal mortality (Sibley & Ann Sipe, 2004) . This led to the current-day reluctance from policy-makers to invest in the training of less qualified CHWs and TBAs (Prata, N. et al., 2011a ). Many believe resources should be focused on training and retaining SBAs, as emphasized in the MDGs (Ronsmans, Campbell, Mcdermott, & Koblinsky, 2002) .
Others argue that TBAs were never armed with appropriate training and technology or reliable referral mechanisms, and misoprostol may now provide a useful tool (Karoshi & Keith, 2009; Prata, N. et al., 2011b) . In combination with evidence for other low-cost interventions such as birth kits and chlorohexidine, there may now be a real opportunity for
TBAs to reduce maternal and newborn mortality (Prata, N. et al., 2011b; Prata, Ndola et al., 2012) . Importantly, CBD resulted in nearly double the coverage of misoprostol compared to distribution through health workers or ANC visits (Smith, J. M. et al., 2013) .
Detraction from a facility-birth strategy
The goal of universal coverage of facility-based births lies at the core of global maternal mortality reduction efforts (Bazzano et al., 2014; United Nations, 2015) . This must be accompanied by adequate numbers of SBAs, equipment and supplies, and surgical care (Murthy & Smith, 2009 ). Governments and policy makers cite concern that advance distribution of misoprostol will detract from facility-based birth strategies (Collins, Mmari, Mullany, Gruber, & Favero, 2016; Geressu et al., 2014; Weeks et al., 2015) . This has not been borne out in Ghana Indonesia (Sanghvi et al., 2004) , Nepal (Khanal et al., 2012) , Liberia (Smith, J.M., Baawo, S.D., et al., 2014) or Afghanistan , where CBD misoprostol programmes found an increase in coverage of SBA and facility-based births. However, this link was not found to be directly causal and other factors such as an increase in SBA or infrastructure investment may have also influenced outcomes. In Ethiopia, place of birth (health facility or home) was not associated with women who received misoprostol during pregnancy .
Scale-up of community-based distribution of misoprostol
The WHO defines scale up as the following: "…deliberate efforts to increase the impact of health service innovations successfully tested in pilot or experimental projects so as to benefit more people and to foster policy and programme development on a lasting basis" (Simmons, Fajans, & Ghiron, 2007, p. viii) . Scale-up of advance distribution of misoprostol for PPH requires supportive policies and a permissive environment to back the intervention (Grenier, 2013; Karanja et al., 2013) . For misoprostol, implementation is also complex, and demands support of national governments to develop national guidelines and policies, including the essential medicines list, procure and distribute the drug, and not least, train health staff and community workers (Robinson, Kapungu, Carnahan, & Geller, 2014) .
Despite explicit commitments from governments, the act of 'going to scale' with community-based distribution and self-administration of misoprostol has been both slow and challenging (Karanja et al., 2013; Oladapo, 2012) . Delayed 2012 endorsement from the WHO for distribution by CHWs, coupled with the challenges outlined above, may limit government buy-in to scale programmes (Smith, H. J. et al., 2015) .
From 2006 to 2012, there were several major developments of international programmes using misoprostol for the prevention of PPH: 15 programmes were initiated in 11 countries Smith, J. M. et al., 2013) . As of 2013, more than 30 countries had registered misoprostol for PPH prevention (Grenier, 2013) . In 
Progress on Scale-up
At the time of writing, documented progress to expand advance distribution of misoprostol for PPH was available from Afghanistan, Bangladesh, Ethiopia, Ghana, Nepal, Nigeria and South Sudan. Published evaluations of scale-up efforts are limited, and only nine evaluations were retrieved (see Table 2 ). Bangladesh and Nepal are the only countries which have documented persistent efforts to move to scale. Three evaluations conducted by the Public Health Institute revealed varying progress on expansion of pilot studies in Ghana and Nigeria, while the project has been discontinued in Ethiopia .
In Afghanistan, the Ministry of Public Health (MoPH) requested the support to conduct a pre and post intervention evaluation of the expansion of advance distribution of misoprostol for PPH (Haver et al., 2016) . Advance distribution of misoprostol in the community significantly increased uterotonic coverage, especially in rural and remote areas (Haver et al., 2016) . Community involvement, including religious leaders and CHWs, in the process of introducing the programme was seen as paramount to its success (Cristy, 2013) . Based on the findings, the MoPH included expansion of misoprostol as a priority in the 2012-2016 Reproductive Health Strategy, and the authors recommended inclusion of ADSMA in the Basic Service Package (Haver et al., 2016) .
In Bangladesh, the 'National Scale-up Plan' was approved in 2010 and expansion began in 2011 in 4 districts with a plan to expand nationally (Family Care International, 2012) . Operations research on scale-up in 29 sub-districts in 6 provinces in Bangladesh found misoprostol distributed through clean birthing kits was effective, feasible and safe, and achieved 60% coverage of uterotonics for women who gave birth at home (Quaiyum, Holston, Hossain, Bell, & Prata, 2011) . Authors recommend extending distribution beyond ANC and using other networks of trained TBAs to increase coverage and scale-up.
The Ethiopian Ministry of Health included misoprostol for the prevention of PPH within the 2011-2015 strategy to reduce maternal and newborn morbidity and mortality . The strategy provided guidance for Health Extension Workers to distribute misoprostol to prevent PPH at home births. Important differences in misoprostol coverage and interpretation of national misoprostol policy were revealed between two regions of Ethiopia (95% coverage in Oromiya Region versus 25% in Amhara Region), likely due to one health authority which permitted wider distribution through skilled providers, health extension workers and community-based volunteers Spangler, Gobezayehu, Getachew, & Sibley, 2014) . The authors recommend implementing a variety of distribution methods to assist in increasing reach (ANC, SBA, TBA and CBW) . A 2014 process evaluation identified that decision makers fear induced abortion and detraction from facility-based births, which have stalled efforts to continue scale-up .
In Ghana, a process evaluation of scale-up found high rates of adherence and acceptance of misoprostol within the community (Azasi, . Misoprostol is integrated into the national health system's continuum of care model and distributed in advance at ANC to women who are in the third trimester. Women are provided with information about how to use the medication appropriately; emphasis is on birthing at a health facility where possible. A community outreach component has CHWs and TBAs conducting home visits to provide further information to women about safe delivery and encourage ANC attendance to receive misoprostol. In 2014, the National PPH Strategy designated scale-up of misoprostol to 30% of the country in regions with the highest burden of home births. Ghana was in a good position to scale-up, yet expansion was proceeding slowly due to limited financial resources for training and procurement as well as the underlying concern that misoprostol may be used for abortion In Nigeria, the programme model relies on TBAs and CHWs to distribute misoprostol within clean birth kits (Otive-Igbuzor, Danmusa, Potts, Coeytaux, & Wells, 2014) . One project has expanded to two districts; further expansion may be limited by the need to create new community health positions given the lack of existing structures (Otive-Igbuzor et al., 2014) . The Ministry of Health has also been reluctant to allow CHWs and TBAs to distribute the drug as they are not considered 'trained community agents' (Wells, E. et al., 2014, p.14) .
South Sudan has been implementing advance distribution of misoprostol for PPH prevention since 2012 as a component of the national PPH programme (Smith, J.M., Alexander, D., et al., 2014) . Advance distribution by home health promoters was found to be safe, feasible and effective with high uterotonic coverage (Smith, J.M., Alexander, D., et al., 2014) . Almost 10, 000 women received uterotonics immediately after birth across the two states from 2013 -2015, a vast improvement from almost no uterotonic coverage prior to launch (Jhpiego, 2015) . While the programme had plans to expand to three additional counties (Jhpiego, 2015) it has now ceased due to funding cuts in 2016.
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A number of countries are in the early phases of scale-up, with no published reports at the time of writing. In
Mozambique, for example, the 2013-2015 Strategy for the Prevention of PPH in the Community includes distribution of misoprostol in the community in 35 districts (Libombo et al., 2013) . Similarly, India, Madagascar and Pakistan have adopted policies or guidance surrounding use of misoprostol for PPH (Larson, Raney, & Ricca, 2014; Sarwar, Cutherell, Noor, Naureen, & Norman, 2015) . Obstacles to implementation persist. In Madagascar, the drug has not yet been registered for prevention of PPH due to concerns about uterine rupture and diversion for abortion (Collins et al., 2016) .
Discussion
This review highlights the evidence and historical timeline for community-based misoprostol for the prevention of PPH, the challenges surrounding its use, and minimal progress on scale-up to date. The scientific literature and operations research remains incomplete, but the available literature suggests that in practice, misoprostol approaches the safety and efficacy of other uterotonics. CBD programmes have consistently demonstrated that CHWs can distribute misoprostol, and women can take the medication appropriately. WHO recommends misoprostol as a safe, affordable and feasible strategy for women who give birth at home and included it on the Essential Medicines List; however, the WHO fell short of endorsing advance community-based distribution. Policy makers in several countries have been reluctant to make it a national priority, in part because of hesitant WHO support and lack of RCTs. Ongoing concerns about safety, efficacy, and aptitude of CHWs plague the history of misoprostol; notably, concerns about diversion and misuse for both induction of labour and induced abortion underpin much of the stagnation in expanding national programmes, including in Ethiopia Spangler et al., 2014) .
Strategies to overcome fear of misuse have been trialed, including branding the tablets as 'safer after-birth' (Vallely et al., 2016 p.2) and establishing strict controls that monitor distribution and retrieval of unused pills (Azasi et al., 2014; Geller et al., 2014; Grenier, 2013; Vallely et al., 2016; Wells, E. et al., 2014) . Strict controls applied in a pilot, however, may not be feasible or sustainable for scale-up due to the heavy administrative burden; health staff and CHWs can encourage women to return unused doses of misoprostol to the health facility without tracking each pill (Azasi et al., 2014) . The politics of who can distribute medicines also threatens the expansion of advance distribution of misoprostol in Nigeria and Ethiopia despite a successful pilot phase. Disquietude about relinquishing power to community-based workers is a recurrent theme through the history of CHW engagement (Perry & Zulliger, 2012) . The advance distribution of misoprostol through antenatal care visits bypasses CHWs altogether, especially where networks are weak; the corollary to that is clear evidence that community based distribution can double coverage (Smith, J. M. et al., 2013) .
We describe several efforts to expand community distribution of misoprostol in Afghanistan, Bangladesh, Ethiopia, Ghana, Nepal, Nigeria and South Sudan. They share a combination of successful pilot studies, central leadership, integration into national reproductive and maternal health strategies, and existing cadres of CHWs or TBAs. Several country examples highlight the need for strategic investments including infrastructure, supplies, equipment and training, combined with careful results-based monitoring are needed to sustain misoprostol programmes and reach those most in need (Freedman et al., 2007) . Documentation of programme expansion is weak, and is not
always congruent with what is happening in practice; for example, colleagues have reported that programmes are expanding in Pakistan and Tanzania, but no formal documentation was found in this review. Even among countries like Ethiopia and South Sudan with successful pilots, explicit government commitment and integration within national policy and strategies, few have been able to operationalize national programmes. Many of the challenges moving from the pilot stage to policy and widespread implementation are expected in scaling interventions (Smith, J.M., De GraftJohnson, Zyaee, Ricca, & Fullerton, 2015; Wells, E. et al., 2014) . Governments may benefit from assistance to develop national guidelines, drug monitoring and distribution, coverage and monitoring plans, inclusion on the national essential medicines list and training staff and CHWs (Robinson et al., 2014) . Lack of clear endorsement of the advance distribution is related to trust in both the CHW and women themselves -not to sell, not to misuse, abort or induce or accelerate labour and ultimately to take misoprostol at the right time (Wells, Elisa et al., 2016) . The WHO argues for further research on safety, efficacy and coverage before they will support CBD (World Health Organization, 2012a) . This review and that of Smith et al (2013) negates many of these concerns. The behavioural outcomes of interest have been successfully studied in operations research studies and are difficult to elucidate in an RCT Potts & Hemmerling, 2006) . Further research is required to better understand the factors that drive national scale-up and institutionalization, and to inform WHO policy recommendations on advance distribution of misoprostol for prevention of PPH.
Conclusion
This review supports the rationale for providing alternative uterotonics to women with little choice but to deliver at home. We conclude that it is a relatively safe, affordable and simple method to prevent PPH for women unable to access health facilities or an SBA. Experience to date suggests that we can simultaneously bolster the coverage and quality of skilled attendance at birth and strengthen health systems to bring advance distribution of misoprostol to scale.
A number of challenges to advancing the use of misoprostol for PPH prevention were highlighted; their influence on decision makers remains poorly understood. Expansion and scale-up of community distribution of misoprostol is ongoing in several countries; however coverage remains incongruent with the large number of pilot studies and evidence in favour of its use. Operations research at the country-level is urgently needed to inform evidence-based decision-making and programme planning, and to understand the critical pathways that allowed decision makers to progress past the pilot phase to scale an evidence-based maternal health intervention. Table 1 : pilot studies published after Smith et al. 2013 (n=7) Additional records forward snowballing (n=79)
Political momentum (n=8)
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